Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare neurologic disease characterized by the chronic consequences of bilirubin toxicity in the globus pallidus, sub-thalamic nuclei, and other brain regions, after exposure to high levels of unconjugated bilirubin in the neonatal period. Symptoms begin after the acute phase of bilirubin encephalopathy in the first year of life, evolve slowly over several years, and include mild to severe extrapyramidal disturbances (especially dystonia and athetosis), auditory neuropathy spectrum disorder, and oculomotor and dental abnormalities.
Biomarker and diagnostic research for chronic bilirubin encephalopathy has been reported in the published literature.
No clinical trials have been registered for chronic bilirubin encephalopathy.
20 publications have been identified in PubMed for chronic bilirubin encephalopathy. Research spans Review / Meta-Analysis (30%), Case Report / Case Series (25%), and Epidemiology / Natural History (15%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 6 | 30% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 2:53 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about chronic bilirubin encephalopathy
Patient case studies
5 |
25% |
Disease patterns and progression | 3 | 15% |
Testing and diagnosis research | 2 | 10% |
Clinical study results | 2 | 10% |
Laboratory research | 2 | 10% |
Wang J (2026). [PMID: 42239022](https://pubmed.ncbi.nlm.nih.gov/42239022/). *Front Public Health*. [Epidemiology / Natural History]
Chen J (2026). [PMID: 41792679](https://pubmed.ncbi.nlm.nih.gov/41792679/). *BMC Pediatr*. [Epidemiology / Natural History]
Lai NM (2026). [PMID: 41784088](https://pubmed.ncbi.nlm.nih.gov/41784088/). *Cochrane Database Syst Rev*. [Review / Meta-Analysis]
Zeiler BB (2026). [PMID: 42028445](https://pubmed.ncbi.nlm.nih.gov/42028445/). *Case Rep Pediatr*. [Case Report / Case Series]
Ansong-Assoku B (2026). [PMID: 30422525](https://pubmed.ncbi.nlm.nih.gov/30422525/). *Unknown Journal*. [Epidemiology / Natural History]
Xu A (2026). [PMID: 41682220](https://pubmed.ncbi.nlm.nih.gov/41682220/). *Healthcare (Basel)*. [Diagnostic / Biomarker]
Farouk ZL (2026). [PMID: 42114958](https://pubmed.ncbi.nlm.nih.gov/42114958/). *BMJ Paediatr Open*. [Case Report / Case Series]
Cortez Ferreira M (2025). [PMID: 40398900](https://pubmed.ncbi.nlm.nih.gov/40398900/). *BMJ Case Rep*. [Case Report / Case Series]
Hamdi MY (2025). [PMID: 41438168](https://pubmed.ncbi.nlm.nih.gov/41438168/). *Pediatric Health Med Ther*. [Review / Meta-Analysis]
Resaz M (2025). [PMID: 40563712](https://pubmed.ncbi.nlm.nih.gov/40563712/). *Brain Sci*. [Case Report / Case Series]